BB Medtech Ag

Actavis (ICE:ACT) Morristown, NJ, 30 December, 2008 -- Actavis today announced that it has acquired the brand name drug Kadian® from King Pharmaceuticals for not more than USD127.5M, based on quarterly sales related milestones, ending 30 June 2010.

Actavis (ICE:ACT) Razgrad, Bulgaria, 8 December 2008 -- Actavis Group, the international generic pharmaceutical company, has today signed a Letter of Intent to sell its manufacturing subsidiary in Bulgaria "Balkanpharma-Razgrad AD" to a newly formed company "Antibiotic-Razgrad AD". The new company has been set up by representatives of current management at the plant in Razgrad with the aim of managing and developing its manufacturing assets.

Actavis (ICE:ACT) Tokyo, 11 November 2008 -- Actavis Group and ASKA Pharmaceutical (Tokyo Stock Exchange: 4514) announce that the companies have concluded a preliminary agreement concerning the establishment of a joint company: Actavis ASKA Co., Ltd. - planning to enter the Japanese generic pharmaceutical market in April 2009.

Actavis (ICE:ACT) Seoul, South Korea, 30 October 2008 -- Actavis, the international generic pharmaceutical company, has entered into an exclusive distribution agreement, for a number of generic products, with J&M Pharma, Co Ltd, a Korean owned and operated pharmaceutical company, headquartered in Seoul, Korea. The agreement is an important step in building Actavis' presence in the Korean generics market.

Actavis (ICE:ACT) Reykjavik, Iceland, 19 August 2008 -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the US Food & Drug Administration to market Bupropion Hydrochloride extended-release tablets (XL) 300mg. Distribution of the product will commence immediately.

Actavis (ICE:ACT) - Actavis EVP Gudbjorg Edda Eggertsdottir appointed deputy CEO - - New Actavis chief complements his team with internal promotions -

Actavis Reykjavik, Iceland, 6 August 2008 -- Actavis Group, the international generic pharmaceuticals company, welcomes the announcement that a pharmacy licence for azithromycin has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA). The successful application relates to the pharmacy licence for Clamelle Azithromycin 500mg Tablets.

Actavis Robert Wessman steps down as the CEO of Actavis Group and is replaced by the Deputy CEO Sigurdur Oli Olafsson

Actavis Reykjavik, Iceland, 10 July 2008 -- Actavis Group, the international generic pharmaceuticals company, today announced the launch of Bicalutamide tablets in the United Kingdom, Germany and France. Bicalutamide Actavis is the first generic version of the oncology drug to be made available in the three markets.